G&E Herbal Biotechnology Co., Ltd. (TPEX:4911)
Taiwan · Delayed Price · Currency is TWD 28.70
-0.50 (-1.71%)
Aug 4, 2026, 1:30 PM CST
G&E Herbal Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 117.55 | 139.2 | 102.06 | 72.4 | 7.38 | -19.88 |
Depreciation & Amortization | 10.65 | 10.61 | 10.38 | 9.33 | 9.4 | 9.33 |
Other Amortization | - | - | - | - | - | 0 |
Loss (Gain) From Sale of Assets | 0.03 | 0.03 | 0.01 | 0.01 | 0 | 0.02 |
Other Operating Activities | -0.31 | 12.32 | 22.5 | 17.98 | 0.71 | 1.67 |
Change in Accounts Receivable | -8.58 | 0.74 | -3.04 | -14.19 | 4.38 | 1.08 |
Change in Inventory | -1.23 | -3.59 | 1.2 | 1.74 | -5.69 | -2.85 |
Change in Accounts Payable | 0.56 | -0.55 | 1.42 | -2 | 2.47 | -0.35 |
Change in Unearned Revenue | -95.12 | -85.1 | -10.01 | 23.39 | 71.39 | 0.28 |
Change in Other Net Operating Assets | -12.26 | -3.49 | 10.16 | 4.82 | 9.92 | 1.52 |
Operating Cash Flow | 11.31 | 70.18 | 134.68 | 113.48 | 99.96 | -9.19 |
Operating Cash Flow Growth | -93.62% | -47.89% | 18.68% | 13.52% | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -3.75 | -3.2 | -5.92 | -5.52 | -2.95 | -1.77 |
Sale (Purchase) of Intangibles | - | - | -0.08 | - | -0.01 | -0.22 |
Investment in Securities | 35 | -95.61 | -83.05 | -82.04 | 5.4 | 9 |
Other Investing Activities | - | - | -0.19 | -0.87 | 0.07 | - |
Investing Cash Flow | 31.25 | -98.82 | -89.24 | -88.43 | 2.51 | 7.01 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | - | -0.88 | -0.77 | -0.12 | - | - |
Net Debt Issued (Repaid) | -0.88 | -0.88 | -0.77 | -0.12 | - | - |
Common Dividends Paid | -44.66 | -44.66 | -31.76 | - | - | - |
Financing Cash Flow | -45.54 | -45.53 | -32.54 | -0.12 | - | - |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | -2.98 | -74.17 | 12.9 | 24.94 | 102.47 | -2.18 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 7.56 | 66.98 | 128.76 | 107.96 | 97.01 | -10.96 |
Free Cash Flow Growth | -95.59% | -47.98% | 19.26% | 11.29% | - | - |
Free Cash Flow Margin | 2.89% | 21.67% | 51.70% | 59.50% | 150.15% | -44.61% |
Free Cash Flow Per Share | 0.11 | 0.97 | 1.87 | 1.57 | 1.41 | -0.16 |
Levered Free Cash Flow | -27.61 | 22.62 | 82.35 | 67.88 | 93.19 | -5.52 |
Unlevered Free Cash Flow | -27.59 | 22.64 | 82.37 | 67.88 | 93.19 | -5.52 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 0.02 | 0.03 | 0.04 | 0 | - | - |
Cash Income Tax Paid | 6.79 | 6.77 | 0.15 | 0.02 | - | - |
Change in Working Capital | -116.62 | -91.98 | -0.28 | 13.76 | 82.47 | -0.32 |